Avenacy Announces Launch of Furosemide for Injection in the U.S. Market
March 20, 2024Furosemide represents the company’s fifth product launch and third product announced during DCAT Week 2024
SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the United States as a therapeutic equivalent generic for Lasix® for Injection (furosemide) approved by the U.S. Food and Drug Administration. Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired.
“The launch of Furosemide for Injection builds on the two launches announced earlier this week and further demonstrates the speed at which we are progressing the business,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “The reception by potential partners and investors to Avenacy at DCAT has been outstanding and, with five products now launched since our formation in October, we look forward to continuing to execute against our goal of launching more than 20 products this year.”
Avenacy’s Furosemide will come in packs of 25 units of 100 mg/10 mL doses. In line with Avenacy’s mission to champion patient safety and streamline patient care, Furosemide for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection. Avenacy will begin shipping Furosemide for Injection to wholesale partners next week. The Company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.
Furosemide for Injection had U.S. sales of approximately $33 million for the twelve months ending in June 2023.1
To learn more about Avenacy’s products or the Company’s exciting growth plans for 2024, please see the Avenacy management team at DCAT Week 2024 taking place in New York City from March 18-21st. To request a meeting with a member of the Avenacy team, please reach out to [email protected].
Warning
Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient’s needs.
Please see link for Full Prescribing Information including the Boxed Warning.
Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral furosemide as soon as practical.
Lasix® is a registered trademark of Sanofi S.A.
1Source: IQVIA
About Avenacy
Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.
Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit http://www.avenacy.com/.
Contacts
Media
FTI Consulting
[email protected]